GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Common Stock

NeoImmuneTech (XKRX:950220) Common Stock : ₩2.55 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Common Stock?

NeoImmuneTech's quarterly common stock increased from Jun. 2023 (₩2.60 Mil) to Sep. 2023 (₩2.66 Mil) but then declined from Sep. 2023 (₩2.66 Mil) to Dec. 2023 (₩2.55 Mil).

NeoImmuneTech's annual common stock increased from Dec. 2021 (₩2.34 Mil) to Dec. 2022 (₩2.51 Mil) and increased from Dec. 2022 (₩2.51 Mil) to Dec. 2023 (₩2.55 Mil).


NeoImmuneTech Common Stock Historical Data

The historical data trend for NeoImmuneTech's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Common Stock Chart

NeoImmuneTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
1.91 1.80 2.34 2.51 2.55

NeoImmuneTech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.51 2.58 2.60 2.66 2.55

NeoImmuneTech Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


NeoImmuneTech (XKRX:950220) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines